NEW YORK – Metastatic colon cancer patients are being undertested for guidelines-backed genomic markers, which means that many of them are losing out on the chance to receive precision therapies, a recently published study suggests.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.